Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
135 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
- Austin Health-Austin Hospital
Heidelberg, Victoria, Australia
- Adelaide Cancer Centre
Kurralta Park, Australia
- Macquarie University Hospital
Macquarie Park, Australia
- London Health Sciences Centre
London, Ontario, Canada
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Sunnybrook Research Institute
Toronto, Ontario, Canada
- Ciusss - Hopital Maisonneuve- Rosemont
Montreal, Quebec, Canada
- Ciusss de L Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
- Chu de Quebec-Universite Laval-Hotel Dieu de Quebec
Québec, Quebec, Canada
- Aalborg University Hospital
Aalborg, Denmark
- Rigshospitalet
Copenhagen, Denmark
- Herlev Hospital
Herlev, Denmark
- Sjaellands Universitetshospital Naestved
Næstved, Denmark
- Institut de Cancerologie de L Ouest Site Paul Papin
Angers, France
- Clinique Sainte Catherine
Avignon, France
- Centre de Lutte Contre Le Cancer Francois Baclesse
Caen, France
- Clinique Victor Hugo
Le Mans, France
- Centre Oscar Lambret
Lille, France
- Centre Leon Berard
Lyon, France
- Institut Du Cancer de Montpellier
Montpellier, France
- Hopital Cochin
Paris, France
- Hopital Saint Louis
Paris, France
- Institut Jean Godinot
Reims, France
- Centre Medico-Chirurgical Foch
Suresnes, France
- C.H.U. de Tours - Hopital Bretonneau
Tours, France
- Institut Gustave Roussy
Villejuif, France
- Universitaetsklinikum Schleswig-Holstein. Campus Luebeck
Lübeck, Schleswig-Holstein, Germany
- Universitaetsklinikum Duesseldorf
Düsseldorf, Germany
- Universitatsklinikum Hamburg-Eppendorf
Hamburg, Germany
- Universitaetsklinikum Jena
Jena, Germany
- Universitaetsklinikum Magdeburg A.O.R.
Magdeburg, Germany
- Klinikum Rechts Der Isar Der Technischen Universitat
München, Germany
- Universitaetsklinikum Tuebingen
Tübingen, Germany
- Orszagos Onkologiai Intezet
Budapest, Hungary
- Uzsoki Utcai Korhaz
Budapest, Hungary
- Somogy Megyei Kaposi Mor Oktato Korhaz
Kaposvár, Hungary
- Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz
Miskolc, Hungary
- Pecsi Tudomanyegyetem Aok
Pécs, Hungary
- Jasz - Nagykun Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet
Szolnok, Hungary
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Dec 2017
- Primary completion
- 27 Jul 2018
- Completion
- 23 Jul 2020
- Last update posted
- 22 Aug 2025
- Registered enrollment
- 84
- Registry id
- NCT03374488
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.